Summary

In patient-reported outcomes for those with recently diagnosed rheumatoid arthritis, treatment with etanercept 25 mg plus methotrexate (MTX) was superior to MTX plus placebo or placebo alone in maintenance of remission and therapeutic effect. This article discusses a poster of the results of A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate [PRIZE; EUCTR2008-00263-85-IT; Emery P et al. EULAR 2013 (poster 0543)].